Cargando…

Tumour stage distribution and survival of malignant melanoma in Germany 2002–2011

BACKGROUND: Over the past two decades, there has been a rising trend in malignant melanoma incidence worldwide. In 2008, Germany introduced a nationwide skin cancer screening program starting at age 35. The aims of this study were to analyse the distribution of malignant melanoma tumour stages over...

Descripción completa

Detalles Bibliográficos
Autores principales: Schoffer, Olaf, Schülein, Stefanie, Arand, Gerlinde, Arnholdt, Hans, Baaske, Dieter, Bargou, Ralf C., Becker, Nikolaus, Beckmann, Matthias W., Bodack, Yves, Böhme, Beatrix, Bozkurt, Tayfun, Breitsprecher, Regine, Buchali, Andre, Burger, Elke, Burger, Ulrike, Dommisch, Klaus, Elsner, Gudrun, Fernschild, Karin, Flintzer, Ulrike, Funke, Uwe, Gerken, Michael, Göbel, Hubert, Grobe, Norbert, Gumpp, Vera, Heinzerling, Lucie, Kempfer, Lana Raffaela, Kiani, Alexander, Klinkhammer-Schalke, Monika, Klöcking, Sabine, Kreibich, Ute, Knabner, Katrin, Kuhn, Peter, Lutze, Stine, Mäder, Uwe, Maisel, Tanja, Maschke, Jan, Middeke, Martin, Neubauer, Andreas, Niedostatek, Antje, Opazo-Saez, Anabelle, Peters, Christoph, Schell, Beatrice, Schenkirsch, Gerhard, Schmalenberg, Harald, Schmidt, Peter, Schneider, Constanze, Schubotz, Birgit, Seide, Anika, Strecker, Paul, Taubenheim, Sabine, Wackes, Matthias, Weiß, Steffen, Welke, Claudia, Werner, Carmen, Wittekind, Christian, Wulff, Jörg, Zettl, Heike, Klug, Stefanie J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5139127/
https://www.ncbi.nlm.nih.gov/pubmed/27919243
http://dx.doi.org/10.1186/s12885-016-2963-0
_version_ 1782472189527719936
author Schoffer, Olaf
Schülein, Stefanie
Arand, Gerlinde
Arnholdt, Hans
Baaske, Dieter
Bargou, Ralf C.
Becker, Nikolaus
Beckmann, Matthias W.
Bodack, Yves
Böhme, Beatrix
Bozkurt, Tayfun
Breitsprecher, Regine
Buchali, Andre
Burger, Elke
Burger, Ulrike
Dommisch, Klaus
Elsner, Gudrun
Fernschild, Karin
Flintzer, Ulrike
Funke, Uwe
Gerken, Michael
Göbel, Hubert
Grobe, Norbert
Gumpp, Vera
Heinzerling, Lucie
Kempfer, Lana Raffaela
Kiani, Alexander
Klinkhammer-Schalke, Monika
Klöcking, Sabine
Kreibich, Ute
Knabner, Katrin
Kuhn, Peter
Lutze, Stine
Mäder, Uwe
Maisel, Tanja
Maschke, Jan
Middeke, Martin
Neubauer, Andreas
Niedostatek, Antje
Opazo-Saez, Anabelle
Peters, Christoph
Schell, Beatrice
Schenkirsch, Gerhard
Schmalenberg, Harald
Schmidt, Peter
Schneider, Constanze
Schubotz, Birgit
Seide, Anika
Strecker, Paul
Taubenheim, Sabine
Wackes, Matthias
Weiß, Steffen
Welke, Claudia
Werner, Carmen
Wittekind, Christian
Wulff, Jörg
Zettl, Heike
Klug, Stefanie J.
author_facet Schoffer, Olaf
Schülein, Stefanie
Arand, Gerlinde
Arnholdt, Hans
Baaske, Dieter
Bargou, Ralf C.
Becker, Nikolaus
Beckmann, Matthias W.
Bodack, Yves
Böhme, Beatrix
Bozkurt, Tayfun
Breitsprecher, Regine
Buchali, Andre
Burger, Elke
Burger, Ulrike
Dommisch, Klaus
Elsner, Gudrun
Fernschild, Karin
Flintzer, Ulrike
Funke, Uwe
Gerken, Michael
Göbel, Hubert
Grobe, Norbert
Gumpp, Vera
Heinzerling, Lucie
Kempfer, Lana Raffaela
Kiani, Alexander
Klinkhammer-Schalke, Monika
Klöcking, Sabine
Kreibich, Ute
Knabner, Katrin
Kuhn, Peter
Lutze, Stine
Mäder, Uwe
Maisel, Tanja
Maschke, Jan
Middeke, Martin
Neubauer, Andreas
Niedostatek, Antje
Opazo-Saez, Anabelle
Peters, Christoph
Schell, Beatrice
Schenkirsch, Gerhard
Schmalenberg, Harald
Schmidt, Peter
Schneider, Constanze
Schubotz, Birgit
Seide, Anika
Strecker, Paul
Taubenheim, Sabine
Wackes, Matthias
Weiß, Steffen
Welke, Claudia
Werner, Carmen
Wittekind, Christian
Wulff, Jörg
Zettl, Heike
Klug, Stefanie J.
author_sort Schoffer, Olaf
collection PubMed
description BACKGROUND: Over the past two decades, there has been a rising trend in malignant melanoma incidence worldwide. In 2008, Germany introduced a nationwide skin cancer screening program starting at age 35. The aims of this study were to analyse the distribution of malignant melanoma tumour stages over time, as well as demographic and regional differences in stage distribution and survival of melanoma patients. METHODS: Pooled data from 61 895 malignant melanoma patients diagnosed between 2002 and 2011 and documented in 28 German population-based and hospital-based clinical cancer registries were analysed using descriptive methods, joinpoint regression, logistic regression and relative survival. RESULTS: The number of annually documented cases increased by 53.2% between 2002 (N = 4 779) and 2011 (N = 7 320). There was a statistically significant continuous positive trend in the proportion of stage UICC I cases diagnosed between 2002 and 2011, compared to a negative trend for stage UICC II. No trends were found for stages UICC III and IV respectively. Age (OR 0.97, 95% CI 0.97–0.97), sex (OR 1.18, 95% CI 1.11–1.25), date of diagnosis (OR 1.05, 95% CI 1.04–1.06), ‘diagnosis during screening’ (OR 3.24, 95% CI 2.50–4.19) and place of residence (OR 1.23, 95% CI 1.16–1.30) had a statistically significant influence on the tumour stage at diagnosis. The overall 5-year relative survival for invasive cases was 83.4% (95% CI 82.8–83.9%). CONCLUSIONS: No distinct changes in the distribution of malignant melanoma tumour stages among those aged 35 and older were seen that could be directly attributed to the introduction of skin cancer screening in 2008. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12885-016-2963-0) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5139127
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-51391272016-12-15 Tumour stage distribution and survival of malignant melanoma in Germany 2002–2011 Schoffer, Olaf Schülein, Stefanie Arand, Gerlinde Arnholdt, Hans Baaske, Dieter Bargou, Ralf C. Becker, Nikolaus Beckmann, Matthias W. Bodack, Yves Böhme, Beatrix Bozkurt, Tayfun Breitsprecher, Regine Buchali, Andre Burger, Elke Burger, Ulrike Dommisch, Klaus Elsner, Gudrun Fernschild, Karin Flintzer, Ulrike Funke, Uwe Gerken, Michael Göbel, Hubert Grobe, Norbert Gumpp, Vera Heinzerling, Lucie Kempfer, Lana Raffaela Kiani, Alexander Klinkhammer-Schalke, Monika Klöcking, Sabine Kreibich, Ute Knabner, Katrin Kuhn, Peter Lutze, Stine Mäder, Uwe Maisel, Tanja Maschke, Jan Middeke, Martin Neubauer, Andreas Niedostatek, Antje Opazo-Saez, Anabelle Peters, Christoph Schell, Beatrice Schenkirsch, Gerhard Schmalenberg, Harald Schmidt, Peter Schneider, Constanze Schubotz, Birgit Seide, Anika Strecker, Paul Taubenheim, Sabine Wackes, Matthias Weiß, Steffen Welke, Claudia Werner, Carmen Wittekind, Christian Wulff, Jörg Zettl, Heike Klug, Stefanie J. BMC Cancer Research Article BACKGROUND: Over the past two decades, there has been a rising trend in malignant melanoma incidence worldwide. In 2008, Germany introduced a nationwide skin cancer screening program starting at age 35. The aims of this study were to analyse the distribution of malignant melanoma tumour stages over time, as well as demographic and regional differences in stage distribution and survival of melanoma patients. METHODS: Pooled data from 61 895 malignant melanoma patients diagnosed between 2002 and 2011 and documented in 28 German population-based and hospital-based clinical cancer registries were analysed using descriptive methods, joinpoint regression, logistic regression and relative survival. RESULTS: The number of annually documented cases increased by 53.2% between 2002 (N = 4 779) and 2011 (N = 7 320). There was a statistically significant continuous positive trend in the proportion of stage UICC I cases diagnosed between 2002 and 2011, compared to a negative trend for stage UICC II. No trends were found for stages UICC III and IV respectively. Age (OR 0.97, 95% CI 0.97–0.97), sex (OR 1.18, 95% CI 1.11–1.25), date of diagnosis (OR 1.05, 95% CI 1.04–1.06), ‘diagnosis during screening’ (OR 3.24, 95% CI 2.50–4.19) and place of residence (OR 1.23, 95% CI 1.16–1.30) had a statistically significant influence on the tumour stage at diagnosis. The overall 5-year relative survival for invasive cases was 83.4% (95% CI 82.8–83.9%). CONCLUSIONS: No distinct changes in the distribution of malignant melanoma tumour stages among those aged 35 and older were seen that could be directly attributed to the introduction of skin cancer screening in 2008. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12885-016-2963-0) contains supplementary material, which is available to authorized users. BioMed Central 2016-12-05 /pmc/articles/PMC5139127/ /pubmed/27919243 http://dx.doi.org/10.1186/s12885-016-2963-0 Text en © The Author(s). 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Schoffer, Olaf
Schülein, Stefanie
Arand, Gerlinde
Arnholdt, Hans
Baaske, Dieter
Bargou, Ralf C.
Becker, Nikolaus
Beckmann, Matthias W.
Bodack, Yves
Böhme, Beatrix
Bozkurt, Tayfun
Breitsprecher, Regine
Buchali, Andre
Burger, Elke
Burger, Ulrike
Dommisch, Klaus
Elsner, Gudrun
Fernschild, Karin
Flintzer, Ulrike
Funke, Uwe
Gerken, Michael
Göbel, Hubert
Grobe, Norbert
Gumpp, Vera
Heinzerling, Lucie
Kempfer, Lana Raffaela
Kiani, Alexander
Klinkhammer-Schalke, Monika
Klöcking, Sabine
Kreibich, Ute
Knabner, Katrin
Kuhn, Peter
Lutze, Stine
Mäder, Uwe
Maisel, Tanja
Maschke, Jan
Middeke, Martin
Neubauer, Andreas
Niedostatek, Antje
Opazo-Saez, Anabelle
Peters, Christoph
Schell, Beatrice
Schenkirsch, Gerhard
Schmalenberg, Harald
Schmidt, Peter
Schneider, Constanze
Schubotz, Birgit
Seide, Anika
Strecker, Paul
Taubenheim, Sabine
Wackes, Matthias
Weiß, Steffen
Welke, Claudia
Werner, Carmen
Wittekind, Christian
Wulff, Jörg
Zettl, Heike
Klug, Stefanie J.
Tumour stage distribution and survival of malignant melanoma in Germany 2002–2011
title Tumour stage distribution and survival of malignant melanoma in Germany 2002–2011
title_full Tumour stage distribution and survival of malignant melanoma in Germany 2002–2011
title_fullStr Tumour stage distribution and survival of malignant melanoma in Germany 2002–2011
title_full_unstemmed Tumour stage distribution and survival of malignant melanoma in Germany 2002–2011
title_short Tumour stage distribution and survival of malignant melanoma in Germany 2002–2011
title_sort tumour stage distribution and survival of malignant melanoma in germany 2002–2011
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5139127/
https://www.ncbi.nlm.nih.gov/pubmed/27919243
http://dx.doi.org/10.1186/s12885-016-2963-0
work_keys_str_mv AT schofferolaf tumourstagedistributionandsurvivalofmalignantmelanomaingermany20022011
AT schuleinstefanie tumourstagedistributionandsurvivalofmalignantmelanomaingermany20022011
AT arandgerlinde tumourstagedistributionandsurvivalofmalignantmelanomaingermany20022011
AT arnholdthans tumourstagedistributionandsurvivalofmalignantmelanomaingermany20022011
AT baaskedieter tumourstagedistributionandsurvivalofmalignantmelanomaingermany20022011
AT bargouralfc tumourstagedistributionandsurvivalofmalignantmelanomaingermany20022011
AT beckernikolaus tumourstagedistributionandsurvivalofmalignantmelanomaingermany20022011
AT beckmannmatthiasw tumourstagedistributionandsurvivalofmalignantmelanomaingermany20022011
AT bodackyves tumourstagedistributionandsurvivalofmalignantmelanomaingermany20022011
AT bohmebeatrix tumourstagedistributionandsurvivalofmalignantmelanomaingermany20022011
AT bozkurttayfun tumourstagedistributionandsurvivalofmalignantmelanomaingermany20022011
AT breitsprecherregine tumourstagedistributionandsurvivalofmalignantmelanomaingermany20022011
AT buchaliandre tumourstagedistributionandsurvivalofmalignantmelanomaingermany20022011
AT burgerelke tumourstagedistributionandsurvivalofmalignantmelanomaingermany20022011
AT burgerulrike tumourstagedistributionandsurvivalofmalignantmelanomaingermany20022011
AT dommischklaus tumourstagedistributionandsurvivalofmalignantmelanomaingermany20022011
AT elsnergudrun tumourstagedistributionandsurvivalofmalignantmelanomaingermany20022011
AT fernschildkarin tumourstagedistributionandsurvivalofmalignantmelanomaingermany20022011
AT flintzerulrike tumourstagedistributionandsurvivalofmalignantmelanomaingermany20022011
AT funkeuwe tumourstagedistributionandsurvivalofmalignantmelanomaingermany20022011
AT gerkenmichael tumourstagedistributionandsurvivalofmalignantmelanomaingermany20022011
AT gobelhubert tumourstagedistributionandsurvivalofmalignantmelanomaingermany20022011
AT grobenorbert tumourstagedistributionandsurvivalofmalignantmelanomaingermany20022011
AT gumppvera tumourstagedistributionandsurvivalofmalignantmelanomaingermany20022011
AT heinzerlinglucie tumourstagedistributionandsurvivalofmalignantmelanomaingermany20022011
AT kempferlanaraffaela tumourstagedistributionandsurvivalofmalignantmelanomaingermany20022011
AT kianialexander tumourstagedistributionandsurvivalofmalignantmelanomaingermany20022011
AT klinkhammerschalkemonika tumourstagedistributionandsurvivalofmalignantmelanomaingermany20022011
AT klockingsabine tumourstagedistributionandsurvivalofmalignantmelanomaingermany20022011
AT kreibichute tumourstagedistributionandsurvivalofmalignantmelanomaingermany20022011
AT knabnerkatrin tumourstagedistributionandsurvivalofmalignantmelanomaingermany20022011
AT kuhnpeter tumourstagedistributionandsurvivalofmalignantmelanomaingermany20022011
AT lutzestine tumourstagedistributionandsurvivalofmalignantmelanomaingermany20022011
AT maderuwe tumourstagedistributionandsurvivalofmalignantmelanomaingermany20022011
AT maiseltanja tumourstagedistributionandsurvivalofmalignantmelanomaingermany20022011
AT maschkejan tumourstagedistributionandsurvivalofmalignantmelanomaingermany20022011
AT middekemartin tumourstagedistributionandsurvivalofmalignantmelanomaingermany20022011
AT neubauerandreas tumourstagedistributionandsurvivalofmalignantmelanomaingermany20022011
AT niedostatekantje tumourstagedistributionandsurvivalofmalignantmelanomaingermany20022011
AT opazosaezanabelle tumourstagedistributionandsurvivalofmalignantmelanomaingermany20022011
AT peterschristoph tumourstagedistributionandsurvivalofmalignantmelanomaingermany20022011
AT schellbeatrice tumourstagedistributionandsurvivalofmalignantmelanomaingermany20022011
AT schenkirschgerhard tumourstagedistributionandsurvivalofmalignantmelanomaingermany20022011
AT schmalenbergharald tumourstagedistributionandsurvivalofmalignantmelanomaingermany20022011
AT schmidtpeter tumourstagedistributionandsurvivalofmalignantmelanomaingermany20022011
AT schneiderconstanze tumourstagedistributionandsurvivalofmalignantmelanomaingermany20022011
AT schubotzbirgit tumourstagedistributionandsurvivalofmalignantmelanomaingermany20022011
AT seideanika tumourstagedistributionandsurvivalofmalignantmelanomaingermany20022011
AT streckerpaul tumourstagedistributionandsurvivalofmalignantmelanomaingermany20022011
AT taubenheimsabine tumourstagedistributionandsurvivalofmalignantmelanomaingermany20022011
AT wackesmatthias tumourstagedistributionandsurvivalofmalignantmelanomaingermany20022011
AT weißsteffen tumourstagedistributionandsurvivalofmalignantmelanomaingermany20022011
AT welkeclaudia tumourstagedistributionandsurvivalofmalignantmelanomaingermany20022011
AT wernercarmen tumourstagedistributionandsurvivalofmalignantmelanomaingermany20022011
AT wittekindchristian tumourstagedistributionandsurvivalofmalignantmelanomaingermany20022011
AT wulffjorg tumourstagedistributionandsurvivalofmalignantmelanomaingermany20022011
AT zettlheike tumourstagedistributionandsurvivalofmalignantmelanomaingermany20022011
AT klugstefaniej tumourstagedistributionandsurvivalofmalignantmelanomaingermany20022011